Gallant Therapeutics

Gallant Therapeutics is a clinical-stage animal health biotechnology company that is setting new standards in animal health by harnessing the power of stem cell therapy to address the root causes of diseases in dogs and cats. Gallant’s ready-to-use mesenchymal stem cell (MSC) therapy pipeline holds the potential to treat a variety of conditions, including canine and feline osteoarthritis (OA) and feline chronic kidney disease (CKD), among others. The first product derived from our uterine-derived platform, aimed at treating feline chronic gingivostomatitis (FCGS), is expected to receive conditional FDA approval by 2025. Gallant’s team, united by a shared love and commitment to animals, includes industry leaders in veterinary regenerative medicine with extensive experience in the development, manufacturing, and commercialization of cell therapy products.